Related Experiment Video
Updated: May 8, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity
Aurélien Marabelle1, Holbrook Kohrt, Ronald Levy
1Authors' Affiliations: Department of Medicine, Division of Oncology, Stanford University, Stanford, California; and Centre de Recherche en Cancérologie de Lyon (CRCL), UMR INSERM U1052 CNRS 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.
Abstract:
Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

